Form D · Pharmaceuticals
Forty Seven, Inc.
Menlo Park, CA · CIK 0001667633
Offering snapshot reported Oct 31, 2017 · SEC filing
- Reported sold
- $75M Offering amount: $75M
- Investors reported
- 32 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 17, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 31, 2017 | Initial | $74,999,998 | No comparison | 32 | SEC filing |
| Mar 3, 2016 | Initial | $34,093,182 | No comparison | 32 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-297746
Source: Form D, filed Oct 31, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Bird | Director |
| Dennis Henner | Director |
| Eric Jensen | Executive |
| Jonathan Mac Quitty | Director |
| Ravindra Majeti | Director |
| Mark A. Mc Camish | Director, Executive |
| Christopher Schaepe | Director |
| Chris Schaepe | Director |
| Irving Weissman | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1490 O'brien Drive, Suite A
Menlo Park, CA, 94025
Menlo Park, CA, 94025